Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Agus

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|January 22, 2021
Cancer Moonshot 2.0David B Agus, Elizabeth M Jaffee, Chi Van Dang
Plos One|December 1, 2016
The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and OlderDavid B Agus, Étienne Gaudette, Dana P Goldman, et al.
Lancet (London, England)|November 10, 2022
COVID-19 and other adult vaccines can drive global disease preventionDavid B Agus, Aurélia Nguyen, Amadou Alpha Sall, et al.
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Ductal adenocarcinoma of the prostateRonald L Shazer, Daniel Luthringer, David B Agus, et al.
Clinical Chemistry|June 29, 2010
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancerYuqiu Jiang, John F Palma, David B Agus, et al.
The Prostate|June 22, 2010
Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signalingSheldon R Mink, Amanda Hodge, David B Agus, et al.
NPJ Breast Cancer|September 14, 2018
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimensRishi R Rawat, Daniel Ruderman, Paul Macklin, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2011
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I studyMitchell E Gross, Lawrence Leichman, Elizabeth S Lowe, et al.
Psycho-Oncology|August 30, 2008
Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and copingKysa M Christie, Beth E Meyerowitz, Antoinette Giedzinska-Simons, et al.
Molecular Cancer Research : MCR|June 10, 2010
Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIsSheldon R Mink, Surabhi Vashistha, Wenxuan Zhang, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|January 22, 2021
Cancer Moonshot 2.0David B Agus, Elizabeth M Jaffee, Chi Van Dang
Plos One|December 1, 2016
The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and OlderDavid B Agus, Étienne Gaudette, Dana P Goldman, et al.
Lancet (London, England)|November 10, 2022
COVID-19 and other adult vaccines can drive global disease preventionDavid B Agus, Aurélia Nguyen, Amadou Alpha Sall, et al.
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Ductal adenocarcinoma of the prostateRonald L Shazer, Daniel Luthringer, David B Agus, et al.
Clinical Chemistry|June 29, 2010
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancerYuqiu Jiang, John F Palma, David B Agus, et al.
The Prostate|June 22, 2010
Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signalingSheldon R Mink, Amanda Hodge, David B Agus, et al.
NPJ Breast Cancer|September 14, 2018
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimensRishi R Rawat, Daniel Ruderman, Paul Macklin, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2011
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I studyMitchell E Gross, Lawrence Leichman, Elizabeth S Lowe, et al.
Psycho-Oncology|August 30, 2008
Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and copingKysa M Christie, Beth E Meyerowitz, Antoinette Giedzinska-Simons, et al.
Molecular Cancer Research : MCR|June 10, 2010
Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIsSheldon R Mink, Surabhi Vashistha, Wenxuan Zhang, et al.
Pageof 8